NCT01018979 - Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Multiple MyelomaNon-Hodgkin LymphomaHodgkin Disease

Interventions

DRUG

TG-0054 (2.24 mg/kg)

TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

DRUG

TG-0054 (3.14 mg/kg)

TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

Trial Locations (6)

Chang-Gung Memorial Hospital Chiayi, Chiayi City

Buddist Tzu Chi General Hospital, Hualien City

Kaohsiung Medical University Hospital, Kaohsiung City

Chang-Gung Memorial Hospital Linkou, Linkou District

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei